DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, ...

Trump Media and Technology Group (DJT) has tied up with asset manager Yorkville America Equities and Index Technologies Group to launch Truth Social-branded Separately Managed Accounts.

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The company’s shares closed yesterda ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

The stock's fall snapped a two-day winning streak.

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.

Dexcom has been cash flow positive for since 2014 and more recently moved into positive earnings territory. While revenue has grown very quickly, research and development expenses and selling, general ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes ...

In addition to Citi, Dexcom also received a Buy from Raymond James’s Jayson Bedford in a report issued yesterday. However, today, Barclays maintained a Hold rating on Dexcom (NASDAQ: DXCM). The ...